MicroTransponder, an Austin, TX-based medical device company, raised $65M in Series F funding.
The round was led by US Venture Partners (USVP) and the syndicate of current investors, Osage University Partners, Action Potential Venture Capital, GPG Ventures, The Vertical Group and Exceller Hunt Ventures, as well as two new investors, Gilde Healthcare and Longitude Capital.
The company intends to use the funds to expand operations and its R&D efforts.
MicroTransponder is a global medical device company committed to developing research-based neuroscience solutions. The company focuses on restoring dignity and function for people suffering from neurological conditions that impair sensory and motor function. Its FDA-approved Vivistim® Paired VNS™ System is a clinically proven medical device that generates improvement in upper limb function for chronic stroke survivors after six weeks of in-clinic occupational or physical therapy.
FinSMEs
13/03/2025